Monday 1 July 2024

The Pharma Letter Podcast — Episode 10 — Will decentralized clinical trials become the new standard?

Pharmaceutical
Simon Wentworth
10 February 2022
the-pharma-letter-podcast-episode-10

More on this story...

Pharmaceutical
How to conduct a Phase III program in a pandemic
4 March 2022
Biotechnology
The Pharma Letter Podcast — Episode 13 — Is there a data capture crisis in biotech?
5 April 2022
Pharmaceutical
Regulators seek to make decentralized trials easier in Europe
20 December 2022
Pharmaceutical
2023: A milestone year for clinical trials?
26 January 2023


More ones to watch >


Today's issue

Pharmaceutical
Boosting crinecerfont, Neurocrine draws from gamut of FDA support
1 July 2024
Biotechnology
Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Pharmaceutical
In ALS, Phase II data show two drugs could be better than one
1 July 2024
Biotechnology
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
Pharmaceutical
Merck & Co sees value in novel prostate cancer drug
1 July 2024
Biotechnology
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Biotechnology
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Pharmaceutical

Boosting crinecerfont, Neurocrine draws from gamut of FDA support
1 July 2024
In ALS, Phase II data show two drugs could be better than one
1 July 2024
Merck & Co sees value in novel prostate cancer drug
1 July 2024
Lonza welcomes new CEO Wolfgang Wienand
1 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze